JP2023523253A5 - - Google Patents

Info

Publication number
JP2023523253A5
JP2023523253A5 JP2022564443A JP2022564443A JP2023523253A5 JP 2023523253 A5 JP2023523253 A5 JP 2023523253A5 JP 2022564443 A JP2022564443 A JP 2022564443A JP 2022564443 A JP2022564443 A JP 2022564443A JP 2023523253 A5 JP2023523253 A5 JP 2023523253A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
approximately
rhsp
calcium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022564443A
Other languages
English (en)
Japanese (ja)
Other versions
JP7798791B2 (ja
JP2023523253A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/028207 external-priority patent/WO2021216584A1/en
Publication of JP2023523253A publication Critical patent/JP2023523253A/ja
Publication of JP2023523253A5 publication Critical patent/JP2023523253A5/ja
Application granted granted Critical
Publication of JP7798791B2 publication Critical patent/JP7798791B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022564443A 2020-04-22 2021-04-20 ウイルス感染症の治療のための肺サーファクタントタンパク質dの使用 Active JP7798791B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063013726P 2020-04-22 2020-04-22
US63/013,726 2020-04-22
US202063072354P 2020-08-31 2020-08-31
US63/072,354 2020-08-31
PCT/US2021/028207 WO2021216584A1 (en) 2020-04-22 2021-04-20 Use of surfactant protein d to treat viral infections

Publications (3)

Publication Number Publication Date
JP2023523253A JP2023523253A (ja) 2023-06-02
JP2023523253A5 true JP2023523253A5 (cg-RX-API-DMAC7.html) 2024-05-02
JP7798791B2 JP7798791B2 (ja) 2026-01-14

Family

ID=78270057

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022564443A Active JP7798791B2 (ja) 2020-04-22 2021-04-20 ウイルス感染症の治療のための肺サーファクタントタンパク質dの使用

Country Status (10)

Country Link
US (1) US20230181697A1 (cg-RX-API-DMAC7.html)
EP (1) EP4138905A4 (cg-RX-API-DMAC7.html)
JP (1) JP7798791B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230019089A (cg-RX-API-DMAC7.html)
AU (1) AU2021258178A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022021423A2 (cg-RX-API-DMAC7.html)
CA (1) CA3180205A1 (cg-RX-API-DMAC7.html)
IL (1) IL297362A (cg-RX-API-DMAC7.html)
MX (1) MX2022013195A (cg-RX-API-DMAC7.html)
WO (1) WO2021216584A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118369582A (zh) * 2022-01-31 2024-07-19 积水医疗株式会社 包含肺表面活性蛋白的液态组合物和包含所述液态组合物的免疫测定试剂盒以及肺表面活性蛋白的保存稳定性提高方法
WO2024097169A1 (en) * 2022-11-01 2024-05-10 National Jewish Health Treatment of coronavirus infections with antimicrobial phospholipid compositions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933032B2 (en) 1998-10-20 2015-01-13 Children's Hospital Medical Center Surfactant protein D for the treatment of disorders associated with lung injury
US6838428B2 (en) 1998-10-20 2005-01-04 Children's Hospital Medical Center Surfactant protein D for the prevention and diagnosis of pulmonary emphysema
US20030221199A1 (en) * 1998-10-20 2003-11-27 Whitsett Jeffrey A. Surfactant protein D for the prevention and diagnosis of pulmonary emphysema
US20120220531A1 (en) * 2011-02-04 2012-08-30 Cincinnati Children's Hospital Medical Center Surfactant protein d for the treatment of disorders associated with lung injury
US20130216499A1 (en) * 2012-02-17 2013-08-22 Wenlin Huang Compositions of recombinant human endostatin adenovirus injections and methods of production
NL2011626C2 (en) * 2013-10-17 2015-04-20 Stichting Tech Wetenschapp Novel polypeptide and uses thereof.
JP7798471B2 (ja) 2017-09-06 2026-01-14 エアウェイ・セラピューティクス・インコーポレイテッド サーファクタントタンパク質d(sp-d)を調製するための方法及び組成物
WO2019050857A1 (en) 2017-09-06 2019-03-14 Airway Therapeutics, LLC METHODS, COMPOSITIONS AND CELLS FOR PREPARING D SURFACTORY PROTEIN (SP-D)
RU2020131642A (ru) * 2018-03-29 2022-04-29 Эйрвэй Терапьютикс, Инк. Способы и композиции, содержащие сурфактантный белок d (sp-d)
MX2020010031A (es) 2018-03-29 2021-01-08 Airway Therapeutics Inc Sistemas y metodos para caracterizar oligomeros de proteina surfactante d (sp-d).
WO2020247675A1 (en) * 2019-06-06 2020-12-10 Spiritus Therapeutics, Inc. Methods for attenuating viral infection and for treating lung injury
KR102205028B1 (ko) * 2020-03-22 2021-01-20 (주)셀트리온 사스-코로나바이러스-2에 중화 활성을 갖는 결합 분자
US11123329B1 (en) * 2020-03-23 2021-09-21 Vicore Pharma Ab Use of angiotensin II type 2 receptor agonist
CN112481417B (zh) * 2020-12-24 2022-05-27 山西大学 新冠肺炎病毒分型及突变位点快速检测方法及试剂盒

Similar Documents

Publication Publication Date Title
CN1523997B (zh) 稳定的白介素2
KR950014915B1 (ko) 탈시알로당단백-포함화합물
Gentile et al. A novel promising therapeutic option against hepatitis C virus: an oral nucleotide NS5B polymerase inhibitor sofosbuvir
Jakeman et al. Exacerbation of bacterial toxicity to infant ferrets by influenza virus: possible role in sudden infant death syndrome
JP5539363B2 (ja) インターフェロンおよびリバビリンとのhcvns3プロテアーゼ阻害剤の組合せ
JP2024099628A5 (cg-RX-API-DMAC7.html)
RU2020131642A (ru) Способы и композиции, содержащие сурфактантный белок d (sp-d)
RU2007119724A (ru) Композиции, содержащие эктинэсайдин и дисахарид
JP2022539077A5 (cg-RX-API-DMAC7.html)
TWI893108B (zh) 司馬魯肽在醫學上的用途
JP2024503265A5 (cg-RX-API-DMAC7.html)
US10344055B2 (en) Composition comprising a peptide and an inhibitor of viral neuraminidase
US8216588B2 (en) Lyophilized preparation comprising influenza vaccine, and method for preparation thereof
JP2007522237A5 (cg-RX-API-DMAC7.html)
WO2022047441A1 (en) Formulations of anti-viral compounds
JP2023539476A5 (cg-RX-API-DMAC7.html)
EP4294454B1 (en) Anti-viral peptides and compositions and methods of use thereof
US20140363396A1 (en) Once daily treatment of hepatitis c with ribavirin and taribavirin
JP7798791B2 (ja) ウイルス感染症の治療のための肺サーファクタントタンパク質dの使用
US20210228605A1 (en) Isomorphs of remdesivir and methods for synthesis of same
KR20070085544A (ko) 간 전달이 개선된 리바비린의 프로드러그
JP2025525990A5 (cg-RX-API-DMAC7.html)
JP2005500981A5 (cg-RX-API-DMAC7.html)
JP2024515555A5 (cg-RX-API-DMAC7.html)
RU2021107534A (ru) Составы, содержащие антитела